{
    "Clinical Trial ID": "NCT00630032",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Docetaxel",
        "  3 cycles of FEC100 (F and C, each at 500 mg/m\u00b2, E 100 mg/m\u00b2, every 3 weeks) followed by 3 cycles of D (100 mg/m\u00b2 every 3 weeks)",
        "  Cyclophosphamide: 500 mg/m\u00b2 every 3 weeks Docetaxel: 100 mg/m\u00b2 every 3 weeks Epirubicin hydrochloride: 100 mg/m\u00b2 every 3 weeks Fluorouracil: 500 mg/m\u00b2 every 3 weeks",
        "INTERVENTION 2: ",
        "  Ixabepilone",
        "  3 cycles of FEC100 (F and C, each at 500 mg/m\u00b2, E 100 mg/m\u00b2, every 3 weeks) followed by 3 cycles of Ixabepilone (40 mg/m\u00b2 every 3 weeks);",
        "  Cyclophosphamide: 500 mg/m\u00b2 every 3 weeks Epirubicin hydrochloride: 100 mg/m\u00b2 every 3 weeks Fluorouracil: 500 mg/m\u00b2 every 3 weeks Ixabepilone: 40 mg/m\u00b2 every 3 weeks"
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "Inclusion criteria:",
        "  Histologically proven invasive unilateral breast cancer (regardless of the type)",
        "  Initial clinical condition compatible with complete initial resection",
        "  No residual macro or microscopic tumor after surgical excision",
        "  Node-positive disease (i.e., positive sentinel node or positive axillary clearance) (N+) or node-negative disease (-) meeting the following criteria :",
        "  Stage II or III disease",
        "  pT >20 mm (T1-4)",
        "  Patients must meet 1 of the following hormone-receptor criteria:",
        "  Node-positive patients: triple-negative* tumor (HER2 negative, estrogen-receptor [ER] negative, and progesterone receptor [PR] negative) OR double-negative (HER2 negative, PR negative, and ER+)",
        "  Node-negative patients: triple-negative* tumor only",
        "  NOTE: *Hormone-receptor negativity is defined as ER <10% and PR <10% by IHC and HER2 negativity is defined as IHC 0-1+ OR IHC 2+ and FISH or CISH negative",
        "  Must be able to begin chemotherapy no later than day 49 after the initial surgery",
        "Exclusion criteria:",
        "  Clinically or radiologically detectable metastases (M0)",
        "  Bilateral breast cancer or contralateral ductal carcinoma in situ",
        "  Any metastatic impairment, including homolateral subclavicular node involvement, regardless of its type",
        "  Any tumor T4a (cutaneous invasion, deep adherence, inflammatory breast cancer)",
        "  HER 2 overexpression defined as IHC 3+ OR IHC 2+ and FISH or CISH positive",
        "  Any clinically or radiologically suspect and non-explored damage to the contralateral breast",
        "  PATIENT CHARACTERISTICS:",
        "Inclusion criteria:",
        "  Female",
        "  Pre- or postmenopausal",
        "  ECOG performance status 0-1",
        "  Peripheral neuropathy grade 1",
        "  Neutrophil count 2,000/mm\u00b3",
        "  Platelet count 100,000/mm\u00b3",
        "  Hemoglobin >9 g/dL",
        "  AST and ALT 1.5 times upper limit of normal (ULN)",
        "  Alkaline phosphatase 2.5 times ULN",
        "  Total bilirubin 1.0 times ULN",
        "  Serum creatinine 1.5 times ULN",
        "  LVEF 50% by MUGA scan or echocardiography",
        "  Not pregnant or nursing",
        "  Negative pregnancy test",
        "  Fertile patients must use effective contraception during and for up to 8 weeks after completion of study treatment",
        "Exclusion criteria:",
        "  Previous cancer (except cutaneous baso-cellular epithelioma or uterine peripheral epithelioma) in the preceding 5 years, including invasive contralateral breast cancer",
        "  Patients with any other concurrent severe and/or uncontrolled medical disease or infection that could compromise participation in the study",
        "  Clinically significant cardiovascular disease within the past 6 months including any of the following:",
        "  Unstable angina",
        "  Congestive heart failure",
        "  Uncontrolled hypertension (i.e., blood pressure >150/90 mm Hg)",
        "  Myocardial infarction",
        "  Cerebral vascular accidents",
        "  Known prior severe hypersensitivity reactions to agents containing Cremophor EL",
        "  Patients with any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule",
        "  Patients deprived of liberty or placed under the authority of a tutor",
        "  PRIOR CONCURRENT THERAPY:",
        "  At least 2 weeks since prior minor surgery (excluding breast biopsy) and adequately recovered",
        "  At least 3 weeks since prior major surgery and adequately recovered",
        "  No prior chemotherapy, hormonal therapy, or radiotherapy",
        "  More than 72 hours since prior and no concurrent treatment with any of the following strong inhibitors of CYP3A4:",
        "  Amiodarone",
        "  Clarithromycin",
        "  Amprenavir",
        "  Delavirdine",
        "  Voriconazole",
        "  Erythromycin",
        "  Fluconazole",
        "  Itraconazole",
        "  Ketoconazole",
        "  Indinavir",
        "  Nelfinavir",
        "  Ritonavir",
        "  Saquinavir",
        "  No concurrent participation in another therapeutic trial involving an experimental drug"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Percentage of Participants With Disease-free Survival (DFS)",
        "  DFS is defined as the interval between the date of randomization and the date of breast cancer relapse (local, regional or distant) or the date of invasive contralateral breast cancer or death from any cause, whichever occurs first",
        "  Time frame: At 5 years",
        "Results 1: ",
        "  Arm/Group Title: Docetaxel",
        "  Arm/Group Description: 3 cycles of FEC100 (F and C, each at 500 mg/m , E 100 mg/m , every 3 weeks) followed by 3 cycles of D (100 mg/m  every 3 weeks)",
        "  Cyclophosphamide: 500 mg/m  every 3 weeks Docetaxel: 100 mg/m  every 3 weeks Epirubicin hydrochloride: 100 mg/m  every 3 weeks Fluorouracil: 500 mg/m  every 3 weeks",
        "  Overall Number of Participants Analyzed: 398",
        "  Measure Type: Number",
        "  Unit of Measure: Percentage of participants  78.97        (74.53 to 82.73)",
        "Results 2: ",
        "  Arm/Group Title: Ixabepilone",
        "  Arm/Group Description: 3 cycles of FEC100 (F and C, each at 500 mg/m , E 100 mg/m , every 3 weeks) followed by 3 cycles of Ixabepilone (40 mg/m  every 3 weeks);",
        "  Cyclophosphamide: 500 mg/m  every 3 weeks Epirubicin hydrochloride: 100 mg/m  every 3 weeks Fluorouracil: 500 mg/m  every 3 weeks Ixabepilone: 40 mg/m  every 3 weeks",
        "  Overall Number of Participants Analyzed: 364",
        "  Measure Type: Number",
        "  Unit of Measure: Percentage of participants  83.37        (79.06 to 86.87)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 207/398 (52.01%)",
        "  Anemia 1/398 (0.25%)",
        "  Aplasia bone marrow 1/398 (0.25%)",
        "  Febrile aplasia 1/398 (0.25%)",
        "  Febrile neutropenia 56/398 (14.07%)",
        "  Lymphocele 0/398 (0.00%)",
        "  Neutropenia 141/398 (35.43%)",
        "  Auricular fibrillation 1/398 (0.25%)",
        "  Non ST segment elevation acute coronary syndrome 0/398 (0.00%)",
        "  Tachycardia 1/398 (0.25%)",
        "  Ear disorder 0/398 (0.00%)",
        "Adverse Events 2:",
        "  Total: 158/364 (43.41%)",
        "  Anemia 2/364 (0.55%)",
        "  Aplasia bone marrow 1/364 (0.27%)",
        "  Febrile aplasia 4/364 (1.10%)",
        "  Febrile neutropenia 27/364 (7.42%)",
        "  Lymphocele 1/364 (0.27%)",
        "  Neutropenia 95/364 (26.10%)",
        "  Auricular fibrillation 0/364 (0.00%)",
        "  Non ST segment elevation acute coronary syndrome 1/364 (0.27%)",
        "  Tachycardia 1/364 (0.27%)",
        "  Ear disorder 1/364 (0.27%)"
    ]
}